Core Insights - Nutriband Inc. reported strong financial results for the six months ended July 31, 2025, with a cash position of $6.9 million and total assets valued at $10.17 million, supporting the development of its lead product, AVERSA™ Fentanyl [1][5] - The company achieved record revenue of $1,289,884 from its kinesiology tape contract manufacturing services, reflecting a year-over-year increase of 50.87% [2] - AVERSA Fentanyl is on track for development, with the NDA relying on a single phase 1 Human Abuse Potential study, eliminating the need for Phase 2 or Phase 3 trials before submission [3] Product Development - AVERSA Fentanyl could become the first and only abuse-deterrent transdermal patch globally, with estimated peak annual sales potential ranging from $80 million to $200 million [4] - The second application, AVERSA Buprenorphine, is projected to reach peak annual sales of up to $130 million [4] - The company emphasizes its AVERSA™ technology, designed to prevent abuse, misuse, and accidental exposure of drugs with abuse potential [6] Financial Position - As of July 31, 2025, Nutriband's stockholders' equity amounted to $8.5 million, indicating a solid financial foundation for ongoing development and commercialization efforts [5]

Core Insights - Nutriband Inc. has made significant progress in the commercialization of its AVERSA technology, aimed at improving the safety of transdermal drugs prone to abuse, particularly pain medications [4][6][10] Company Achievements - The company has established a partnership with Kindeva Drug Delivery to develop AVERSA Fentanyl, which is expected to be the first opioid pain patch with abuse deterrent properties [5][8] - Nutriband has expanded its intellectual property portfolio, securing patents in 46 countries, including recent approvals in China, Hong Kong, and the United States [9][15] - The company raised $8.4 million in April 2024 through a non-brokered private placement, primarily from existing shareholders, to support its development efforts [8] Financial Outlook - AVERSA Fentanyl is projected to achieve peak annual sales between $80 million and $200 million, while AVERSA Buprenorphine is estimated to reach peak sales of $70 million to $130 million [6] - The Pocono Pharma subsidiary is expected to have a strong revenue year in 2025 due to expanding collaborations in contract manufacturing services [11] Future Goals - Nutriband aims to initiate a pivotal Human Abuse Liability clinical trial for AVERSA Fentanyl in 2025, supporting an NDA filing with the FDA [10] - The company plans to explore international partnerships for its AVERSA intellectual property as it approaches the NDA filing [10]

As filed with the Securities and Exchange Commission on June 23, 2023 Registration No. 333-271791 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Nutriband Inc. (Exact name of registrant as specified in its charter) (State or jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 2834 81-1118176 (I.R.S. Employer Identification No.) Orlando, Florida ...

As filed with the Securities and Exchange Commission on May 10, 2023 Registration No. 333-_____ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Nutriband Inc. (Exact name of registrant as specified in its charter) (State or jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 2834 81-1118176 (I.R.S. Employer Identification No.) 121 South Orange Ave., Suite 1500 O ...